Who are Methotrexate - Delay's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Trimethoprim, Gentamicin, Wellcovorin, Klaron, Sulfamethoxazole Trimethoprim Combination, Quinine plus sulfadoxine-pyrimethamine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/methotrexate-delay.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Methotrexate - Delay — Competitive Intelligence Brief

Methotrexate - Delay (Methotrexate - Delay) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite. Area: Oncology, Immunology, Rheumatology.

phase 3 Antimetabolite Dihydrofolate reductase Oncology, Immunology, Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

Methotrexate - Delay (Methotrexate - Delay) — University Hospital, Montpellier. Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, disrupting DNA synthesis and cell division.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Methotrexate - Delay TARGET	Methotrexate - Delay	University Hospital, Montpellier	phase 3	Antimetabolite	Dihydrofolate reductase
Trimethoprim	TRIMETHOPRIM	Dr Reddys Labs Sa	marketed	Sulfonamide Antimicrobial [EPC]	Dihydrofolate reductase	1973-01-01
Gentamicin	Gentamicin Sulfate	Merck & Co.	marketed	gentamicin	Dihydrofolate reductase	1970-01-01
Wellcovorin	leucovorin	Pfizer Japan Inc	marketed	Folate Analog	Dihydrofolate reductase	1952-01-01
Klaron	SULFACETAMIDE	Merck & Co.	marketed	Sulfonamide Antibacterial	Dihydrofolate reductase	1945-01-01
Sulfamethoxazole Trimethoprim Combination	Sulfamethoxazole Trimethoprim Combination	Baylor Research Institute	marketed	Sulfonamide-dihydrofolate reductase inhibitor combination	Dihydropteroate synthase; Dihydrofolate reductase
Quinine plus sulfadoxine-pyrimethamine	Quinine plus sulfadoxine-pyrimethamine	Albert Schweitzer Hospital	marketed	Antimalarial combination	Plasmodium DNA/protein synthesis; dihydrofolate reductase; dihydropteroate synthase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimetabolite class)

Grupo Espanol Multidisciplinario del Cancer Digestivo · 2 drugs in this class
NRG Oncology · 2 drugs in this class
Bristol-Myers Squibb · 1 drug in this class
EMD Serono Research & Development Institute, Inc. · 1 drug in this class
GERCOR - Multidisciplinary Oncology Cooperative Group · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Centre Oscar Lambret · 1 drug in this class
Iwate Medical University · 1 drug in this class
Janssen Research & Development, LLC · 1 drug in this class
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Methotrexate - Delay — Competitive Intelligence Brief. https://druglandscape.com/ci/methotrexate-delay. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab